LabGenomics USA, a subsidiary of LabGenomics Co., Ltd., has completed the acquisition of QDx Pathology, a prominent player in the field of molecular and diagnostic pathology.
This acquisition represents a significant development for both LabGenomics USA and QDx Pathology, with far-reaching implications for the industry.
QDx Pathology is a well-established diagnostic service company with a 16-year history of offering expert pathology consultations and rapid molecular testing services to healthcare professionals and their patients.
The acquisition was officially announced on August 17th, with the deal being signed on August 16th, 2023, following a three-month-long acquisition process. This strategic move aligns with LabGenomics USA’s expansion plans into the North American market.
Junghee Cho, Ph.D., CEO of LabGenomics USA, expressed the significance of this partnership, stating that it is an honor to establish a North American presence with QDx, a leader in the clinical laboratory service market in the United States.
LabGenomics USA aims to offer innovative and cost-effective diagnostic solutions in the U.S. market by leveraging LabGenomics’ expertise in next-generation sequencing (NGS)-based molecular diagnosis.
Tim Rich, CEO of QDx Pathology, shared his excitement about the acquisition and the opportunities it presents. By combining their strengths and resources, both companies are well-positioned to expand their range of diagnostic tests and services, ultimately benefiting their customers and the healthcare industry as a whole.
